On the heels of the FDA lifting its clinical hold on lead product BPX-501, Bellicum announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All shares of common stock to be sold in the offering will be offered by Bellicum.

Citigroup and Jefferies LLC are acting as lead book-running managers for the offering. Bellicum expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 1,050,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

BPX-501 is an adjunct T-cell therapy administered after allogeneic HSCT (hematopoietic stem cell transplants), comprising genetically modified donor T cells incorporating Bellicum’s CaspaCIDe® safety switch. Bellicum currently has four clinical trials underway involving BPX-501.

Bellicum shares have risen by 30+ percent since the FDA's announcement. However shares are down 7% in after hours trading as of this writing.